Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lifestyle makeover tested as MS symptom fighter

NCT ID NCT07589062

Disease control Sponsor: New York University Abu Dhabi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a structured 12-week program focusing on nutrition, exercise, sleep, and stress management can improve fatigue, physical function, and quality of life in people with relapsing-remitting multiple sclerosis. Thirty participants will first be observed for 12 weeks, then complete the program with online exercise sessions, meal plans, and daily habit tracking. Researchers will also check if lifestyle changes affect inflammation and immune markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multi-domain lifestyle program (nutrition, exercise, sleep, stress management)
What this could lead to
If it works, this could point toward a practical, drug-free way to manage MS symptoms and improve daily life.
What could go wrong
This is a small, early-stage trial with only 30 participants and no control group, so results may not apply widely. The program requires significant commitment, and benefits may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed MS diagnosis (McDonald criteria) * EDSS score ≤ 6.5 (i.e., ambulatory with or without assistance) * Stable disease-modifying therapy for ≥ 3 months * Age 18-50 * Proficiency in English or Arabic * Clearance to participate in a structured exercise program * Ability to walk, sit and stand independently, and perform light-to-moderate movement patterns, even with modifications * Ability and digital literacy to interact with the bilingual HEAL MS mobile app and * Access to a computer for participation in online sessions Exclusion Criteria: * Significant cognitive impairment affecting app use and comprehension of the intervention * MS relapse within the past 3 months * Pregnancy or planned pregnancy * Unmanaged psychiatric disorders * Other immune-related or chronic inflammatory or metabolic diseases * Concurrent enrollment in another lifestyle intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fatigue inborn mitochondrial metabolism disorder multiple sclerosis Neuroinflammatory Diseases relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis Multiple sclerosis (MS) - relapsing-remitting

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yas Clinic

    Abu Dhabi, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.